SORRENTO THERAPEUTICS INC (SRNE) Financial Statements
Historical financial data — 25 statements covering FY2016–FY2021
SORRENTO THERAPEUTICS INC
SORRENTO THERAPEUTICS INC's revenue increased 32.3% year over year, from $40.0M to $52.9M.
Net income decreased 43.5% over the same period, from $-298.5M to $-428.3M.
Over the 5-year period from FY2016 to FY2021, revenue grew by 549% in total.
Total debt increased by 19.9% to $110.6M.
The debt-to-equity ratio stands at 1.40, indicating a elevated leverage profile.
Operating cash flow declined 76.7% to $-281.8M.
SORRENTO THERAPEUTICS INC maintains a negative net profit margin of -809.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2019 | $18.4M+45.8% | $-229.2M | $7.6M | $-226.8M | $-137.0M | $560.9M | $234.4M | $45.9M |
| Q1 FY2020 | $7.7M-58.0% | $-65.2M | $-43.2M | $-43.2M | $-38.5M | $536.6M | $183.0M | $101.0M |
| Q2 FY2020 | $16.7M+116.7% | $-142.9M | $12.0M | $-90.9M | $-76.1M | $533.1M | $147.0M | $137.3M |
| Q3 FY2020 | $28.5M+70.3% | $-227.0M | $21.1M | $-174.0M | $-118.7M | $602.1M | $149.5M | $205.4M |
| Q1 FY2021 | $14.3M-49.9% | $2.5M | $-84.9M | $-84.9M | $-48.1M | $613.6M | $80.0M | $231.4M |
| Q2 FY2021 | $27.8M+94.8% | $-164.1M | $21.3M | $-185.5M | $-126.6M | $778.9M | $82.6M | $186.2M |
| Q3 FY2021 | $39.8M+43.4% | $-283.9M | $29.9M | $-286.8M | $-209.7M | $752.8M | $83.5M | $131.5M |
| Q2 FY2022 | $29.8M-25.1% | $-259.6M | $18.4M | $-225.2M | $-164.3M | $632.1M | $83.1M | $132.0M |
Balance Sheet Summary (Latest Period)
Total Assets
$694.8M
Total Liabilities
$616.7M
Total Equity
$78.7M
Cash & Equivalents
$126.9M
Total Debt
$110.6M
Current Assets
$173.0M
Current Liabilities
$139.5M
Retained Earnings
$-1.39B
Current Price: $0.00
Sector: Other